NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $1.05 -0.05 (-4.55%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$1.05▼$1.1350-Day Range$1.04▼$4.6552-Week Range$0.92▼$7.98Volume91,256 shsAverage Volume287,806 shsMarket Capitalization$15.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media About MIRA Pharmaceuticals Stock (NASDAQ:MIRA)MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.Read More MIRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRA Stock News HeadlinesDecember 20, 2023 | investing.comMira Pharmaceuticals (MIRA) Earnings Dates & ReportsDecember 18, 2023 | msn.comMIRA Pharmaceuticals files to sell up to 1.7M shares for holdersDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 16, 2023 | seekingalpha.comIPO Update: Telomir Pharmaceuticals Proposes IPO TermsDecember 4, 2023 | markets.businessinsider.comMIRA Pharma: AI Simulation On MIRA1a Shows Advantages Over Plant-Based Medical MarijuanaDecember 4, 2023 | finance.yahoo.comMIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNovember 29, 2023 | finance.yahoo.comMIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%November 27, 2023 | finance.yahoo.comMIRA Makes Great Deal for Potential BlockbusterDecember 31, 2023 | Behind the Markets (Ad)FINAL OFFER: $9 for a FULL YEAR of stock picksWe're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?November 22, 2023 | seekingalpha.comAQB, BIVI and SHOT among mi-day moversNovember 22, 2023 | morningstar.comMira Pharmaceuticals IncNovember 21, 2023 | morningstar.comMira Pharmaceuticals Inc MIRANovember 21, 2023 | finance.yahoo.comMIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNovember 21, 2023 | finance.yahoo.comMIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNovember 20, 2023 | markets.businessinsider.comMIRA Pharma Partners With MIRALOGX For Licensing Agreement For Ketamir-2November 20, 2023 | marketwatch.comShares of MIRA Pharmaceutical Soar 92% on Licensing Agreement for Ketamine TreatmentNovember 20, 2023 | msn.comWhy Is Depression Focused MIRA Pharmaceuticals Stock Trading Higher Today?November 20, 2023 | nz.finance.yahoo.comOpenAI appoints former Twitch boss Emmett Shear CEO after shock departure of Sam AltmanNovember 20, 2023 | finance.yahoo.comMIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNovember 20, 2023 | finance.yahoo.comMIRA: Developing Cannabis with Benefits and Without Side EffectsNovember 20, 2023 | finance.yahoo.comMIRA Continues to Pursue New Pain ReliefNovember 20, 2023 | finance.yahoo.comMIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2August 25, 2023 | benzinga.comGeorge Cappy Mira Pharmaceuticals, IncAugust 14, 2023 | finance.yahoo.comMIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THCAugust 14, 2023 | finance.yahoo.comMIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day PodcastSee More Headlines Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)1/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CUSIPN/A CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,780,000Free FloatN/AMarket Cap$15.52 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Adam Kaplin M.D. (Age 56)Ph.D., Co-Founder, President & Chief Science Officer Comp: $50kDr. Christopher C. Chapman Jr. (Age 70)M.D., Executive Chairman Mr. Erez Aminov (Age 45)CEO & Director Ms. Michelle Yanez M.B.A. (Age 51)CFO, Secretary & Treasurer Mr. Christos Nicholoudis Esq. (Age 33)General Counsel & Director Key CompetitorsSensei BiotherapeuticsNASDAQ:SNSEAytu BioPharmaNASDAQ:AYTUCalciMedicaNASDAQ:CALCBullfrog AINASDAQ:BFRGNeuroBo PharmaceuticalsNASDAQ:NRBOView All CompetitorsInsidersBrian Patrick McnultySold 46,005 sharesTotal: $71,307.75 ($1.55/share)Brian Patrick McnultySold 19,053 sharesTotal: $30,675.33 ($1.61/share)Brian Patrick McnultySold 27,733 sharesTotal: $81,812.35 ($2.95/share)Brian Patrick McnultySold 61,331 sharesTotal: $244,097.38 ($3.98/share)Brian Patrick McnultySold 7,399 sharesTotal: $29,448.02 ($3.98/share)View All Insider Transactions MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed in 2023? MIRA Pharmaceuticals' stock was trading at $6.01 at the start of the year. Since then, MIRA stock has decreased by 82.5% and is now trading at $1.05. View the best growth stocks for 2023 here. When is MIRA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, January 5th 2024. View our MIRA earnings forecast. When did MIRA Pharmaceuticals IPO? (MIRA) raised $9 million in an IPO on Thursday, August 3rd 2023. The company issued 1,275,000 shares at a price of $7.00 per share. When does MIRA Pharmaceuticals' lock-up period expire? MIRA Pharmaceuticals' lock-up period expires on Tuesday, January 30th. MIRA Pharmaceuticals had issued 1,275,000 shares in its IPO on August 3rd. The total size of the offering was $8,925,000 based on an initial share price of $7.00. After the end of MIRA Pharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRA) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.